Similar articles for PMID: 22933817

Year	Number of Results
2001	1
2004	2
2005	1
2006	3
2007	1
2008	2
2009	4
2010	6
2011	3
2012	6
2013	5
2014	6
2015	11
2016	10
2017	4
2018	6
2019	6
2020	3
2021	6
2022	6
2023	3
2024	0

1

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.

Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, Shah BB, Fox S, Prashanth LK, Phielipp N, Lang AE. Pondal M, et al. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):130-5. doi: 10.1136/jnnp-2012-302684. Epub 2012 Aug 29. J Neurol Neurosurg Psychiatry. 2013. PMID: 22933817

2

Dopamine agonist withdrawal syndrome in Parkinson disease.

Rabinak CA, Nirenberg MJ. Rabinak CA, et al. Arch Neurol. 2010 Jan;67(1):58-63. doi: 10.1001/archneurol.2009.294. Arch Neurol. 2010. PMID: 20065130

3

Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.

Patel S, Garcia X, Mohammad ME, Yu XX, Vlastaris K, O'Donnell K, Sutton K, Fernandez HH. Patel S, et al. J Neurol Sci. 2017 Aug 15;379:308-311. doi: 10.1016/j.jns.2017.06.022. Epub 2017 Jun 16. J Neurol Sci. 2017. PMID: 28716269

4

Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.

Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, Bhidayasiri R, Foote KD, Bowers D, Ward H, Okun MS. Limotai N, et al. Int J Neurosci. 2012 Mar;122(3):145-53. doi: 10.3109/00207454.2011.633722. Epub 2011 Dec 6. Int J Neurosci. 2012. PMID: 22023411

5

Dopamine agonist withdrawal syndrome: implications for patient care.

Nirenberg MJ. Nirenberg MJ. Drugs Aging. 2013 Aug;30(8):587-92. doi: 10.1007/s40266-013-0090-z. Drugs Aging. 2013. PMID: 23686524 Review.

6

Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.

Solla P, Fasano A, Cannas A, Mulas CS, Marrosu MG, Lang AE, Marrosu F. Solla P, et al. Parkinsonism Relat Disord. 2015 Aug;21(8):968-71. doi: 10.1016/j.parkreldis.2015.05.018. Epub 2015 Jun 10. Parkinsonism Relat Disord. 2015. PMID: 26071817

7

Dopamine agonist withdrawal syndrome: A comprehensive review.

Yu XX, Fernandez HH. Yu XX, et al. J Neurol Sci. 2017 Mar 15;374:53-55. doi: 10.1016/j.jns.2016.12.070. Epub 2017 Jan 2. J Neurol Sci. 2017. PMID: 28104232 Review.

8

Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.

Edwards MJ. Edwards MJ. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):120. doi: 10.1136/jnnp-2012-303570. Epub 2012 Sep 19. J Neurol Neurosurg Psychiatry. 2013. PMID: 22993451 No abstract available.

9

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Garcia-Ruiz PJ, et al. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):840-4. doi: 10.1136/jnnp-2013-306787. Epub 2014 Jan 16. J Neurol Neurosurg Psychiatry. 2014. PMID: 24434037

10

A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease.

Chaudhuri KR, Todorova A, Nirenberg MJ, Parry M, Martin A, Martinez-Martin P, Rizos A, Henriksen T, Jost W, Storch A, Ebersbach G, Reichmann H, Odin P, Antonini A. Chaudhuri KR, et al. Mov Disord Clin Pract. 2015 Mar 16;2(2):170-174. doi: 10.1002/mdc3.12141. eCollection 2015 Jun. Mov Disord Clin Pract. 2015. PMID: 30713891 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

79 results

Results by year